GSK plc (LON:GSK) Receives Average Recommendation of "Moderate Buy" from Analysts

GSK plc (LON:GSK - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is GBX 1,805.83 ($22.05).

Several research firms have commented on GSK. Berenberg Bank dropped their price target on shares of GSK from GBX 1,820 ($22.22) to GBX 1,600 ($19.53) and set a "buy" rating for the company in a research note on Friday, November 29th. JPMorgan Chase & Co. restated an "underweight" rating on shares of GSK in a report on Tuesday, January 7th.

GSK Trading Down 1.4 %

Shares of GSK traded down GBX 19.05 ($0.23) during trading on Tuesday, reaching GBX 1,311.95 ($16.02). 8,243,084 shares of the company traded hands, compared to its average volume of 71,483,508. GSK has a twelve month low of GBX 1,282.50 ($15.66) and a twelve month high of GBX 1,823.50 ($22.26). The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04. The stock has a 50-day simple moving average of GBX 1,348.92 and a 200-day simple moving average of GBX 1,475.52. The stock has a market cap of £53.53 billion, a PE ratio of 1,161.02, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK Announces Dividend

The business also recently disclosed a dividend, which was paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th were paid a GBX 15 ($0.18) dividend. The ex-dividend date was Thursday, November 14th. This represents a yield of 1.03%. GSK's dividend payout ratio is presently 5,309.73%.

Insiders Place Their Bets

In related news, insider Jonathan Symonds bought 1,500 shares of the stock in a transaction on Friday, December 20th. The shares were bought at an average cost of GBX 1,315 ($16.05) per share, for a total transaction of £19,725 ($24,081.31). Over the last 90 days, insiders have bought 8,658 shares of company stock valued at $11,950,792. 1.61% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.